Virtual Library
Start Your Search
J. Scheele
Author of
-
+
Best abstracts selected from submissions 3 (ID 3)
- Event: ACLC 2018
- Type: Oral Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/08/2018, 16:20 - 17:00, Crystal Ballroom 1
-
+
OA06 - Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: (ID 140)
16:20 - 17:00 | Author(s): J. Scheele
- Abstract
Background:
The MET pathway is frequently deregulated in human cancer, leading to dependency on MET signaling and hence this represents a potential therapeutic target in non-small cell lung cancer (NSCLC). MET alterations include MET exon 14-skipping mutations (METex14+) and MET amplification (METamp); these occur in ~3% and 0.4
-
+
Best abstracts selected from submissions 7 (ID 5)
- Event: ACLC 2018
- Type: Oral Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 11/09/2018, 16:20 - 17:00, Jade Ballroom
-
+
OA14 - Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (ID 67)
16:20 - 17:00 | Author(s): J. Scheele
- Abstract
Background:
Non-small cell lung cancer (NSCLC) can acquire resistance to EGFR tyrosine kinase inhibitors (EGFR TKIs) via MET activation; dual MET/EGFR inhibition may have potential in EGFR TKI-resistant NSCLC. Tepotinib is a potent, selective MET TKI. We report randomized phase 2 data from a phase 1b/2 signal detection trial of tepotinib+gefitinib vs chemotherapy (pemetrexed + cisplatin/carboplatin) in patients with MET+/EGFR+T790M- NSCLC (NCT01982955).
Method:
Asian patients with advanced MET+ (IHC2+, IHC3+, gene amplification) NSCLC, acquired resistance to 1st-line EGFR TKI and ECOG performance status 0